June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Autoimmune retinopathy treated with fluocinolone acetate intravitreal implant (Retisert)
Author Affiliations & Notes
  • Sana Idrees
    University of Rochester Medical Center, Flaum Eye Institute, Rochester, New York, United States
  • Zoe Williams
    University of Rochester Medical Center, Flaum Eye Institute, Rochester, New York, United States
  • David DiLoreto, Jr
    University of Rochester Medical Center, Flaum Eye Institute, Rochester, New York, United States
  • Footnotes
    Commercial Relationships   Sana Idrees, None; Zoe Williams, None; David DiLoreto, Jr, None
  • Footnotes
    Support  Research to Prevent Blindness, New York, New York
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 314. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sana Idrees, Zoe Williams, David DiLoreto, Jr; Autoimmune retinopathy treated with fluocinolone acetate intravitreal implant (Retisert). Invest. Ophthalmol. Vis. Sci. 2020;61(7):314.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To describe the outcomes of three cases of autoimmune retinopathy (AIR) in patients treated with sustained release fluocinolone acetonide intravitreal implant.

Methods : This is a case series of three patients with autoimmune retinopathy treated with fluocinolone acetonide intravitreal implant due to inability to tolerate systemic immunosuppression. Visual acuity (VA), retinal optical coherence tomography (OCT), and visual field (VF) were followed post-operatively.

Results : Case 1. A 64 year old male presented with cancer associated retinopathy (CAR) secondary to lung carcinoma. He had a good initial response to intravenous immunoglobulin and steroids, but was unable to tolerate steroids due to side effects or mycophenolate mofetil due to leukopenia. He underwent implantation of intravitreal fluocinolone acetonide in the right eye. His VA pre-operatively was 20/40 and one week post-operatively was 20/50 with a stable VF and OCT. His VA remained stable for 6 months until his death.

Case 2. An 87 year old male presented with autoimmune retinopathy. He initially refused oncologic work-up or systemic treatment and developed progressive vision loss. Intravitreal triamcinolone injections stabilized the disease for a limited duration. He did not tolerate treatment with mycophenolate mofetil. His pre-operative VA was 20/150 in both eyes. After bilateral intravitreal fluocinolone acetonide implantation, he was 20/200 in both eyes at 15 months with relatively stable OCTs. At 2 years, he was 2/200 in the right eye and 1/200 in the left eye with worsening thinning on OCTs.

Case 3. A 68 year old female presented with CAR in the setting of breast cancer. She had progressive VF loss despite intravitreal triamcinolone injections and worsened liver function with mycophenolate mofetil. She was switched to rituximab and underwent bilateral intravitreal fluocinolone acetonide implantation. At 8 months post-operatively, she maintained VA of 20/25 in both eyes and stable OCTs, but continued to demonstrate worsening peripheral VF. Intravenous immunoglobulin was started and VF stabilized 13 months post-operatively.

Conclusions : This case series demonstrates that adjunctive local treatment with a long acting intravitreal steroid implant should be considered in the treatment paradigm of patients with autoimmune retinopathy, especially when systemic immunosuppression is not well tolerated.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×